Control of kappa immunoglobulin light-chain gene expression requires the interaction of tissue specific and developmentally regulated DNA-binding proteins with the kappa gene enhancer. Deletion of enhancer sequences upstream from the NF-kB binding site has been shown to impair enhancer function, implying additional proteins may interact with these sequences. In surveying this region for sites of protein binding, a novel DNA-protein interaction, designated kBF-A, was detected. The binding activity of this factor appears to be specific to activated pre-B cells and correlates with high level induction of kappa transcription in these cells.
No takes yet. Share an insight, caveat, or question.
Neims et al. (1990) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: